MARKET

PIRS

PIRS

Pieris Pharmaceu
NASDAQ
11.93
-0.07
-0.58%
After Hours: 11.42 -0.51 -4.27% 18:10 04/24 EDT
OPEN
11.71
PREV CLOSE
12.00
HIGH
11.93
LOW
11.17
VOLUME
40.07K
TURNOVER
0
52 WEEK HIGH
80.80
52 WEEK LOW
10.89
MARKET CAP
14.75M
P/E (TTM)
-0.5472
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PIRS last week (0415-0419)?
Weekly Report · 2d ago
Pieris Pharmaceuticals OKs 1-for-80 reverse stock split
Seeking Alpha · 5d ago
Pieris Pharmaceuticals Enacts Reverse Stock Split for NASDAQ Compliance
TipRanks · 6d ago
PIERIS PHARMACEUTICALS- ANNOUNCES 1-FOR-80 REVERSE STOCK SPLIT
Reuters · 6d ago
PIERIS PHARMACEUTICALS INC: COMMON STOCK TRADING ON A REVERSE SPLIT-ADJUSTED BASIS WILL BEGIN AT MARKET OPEN ON TUESDAY, APRIL 23, 2024.
Reuters · 6d ago
Weekly Report: what happened at PIRS last week (0408-0412)?
Weekly Report · 04/15 09:55
Weekly Report: what happened at PIRS last week (0401-0405)?
Weekly Report · 04/08 09:57
Weekly Report: what happened at PIRS last week (0325-0329)?
Weekly Report · 04/01 09:56
More
About PIRS
Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.

Webull offers Pieris Pharmaceuticals Inc stock information, including NASDAQ: PIRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PIRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PIRS stock methods without spending real money on the virtual paper trading platform.